Management of extraintestinal manifestations and other complications of inflammatory bowel disease

被引：45
作者：
Loftus Jr. E.V. [1 ]
机构：
[1] Div. of Gastroenterology/Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, 200 First Street, SW
来源：
Current Gastroenterology Reports | 2004年 / 6卷 / 6期
关键词：
Ulcerative Colitis; Infliximab; Uveitis; Primary Sclerosing Cholangitis; Pyoderma Gangrenosum;
D O I：
10.1007/s11894-004-0073-7
中图分类号：
学科分类号：
摘要：
The past 18 months have seen many studies of the prevalence, pathogenesis, and treatment of the extraintestinal manifestations of inflammatory bowel disease (IBD). Inhibitors of tumor necrosis factor alpha have shown effectiveness in randomized trials for the treatment of spondyloarthropathies and ocular manifestations. Open-label studies suggest that these agents may be effective for pyoderma gangrenosum as well. The epidemiology of primary sclerosing cholangitis (PSC), and its relationship to IBD, is becoming clearer. Colorectal neoplasia in PSC remains an important clinical problem. Osteoporosis occurs more commonly in IBD, but the relative importance of corticosteroid use versus underlying chronic bowel inflammation as risk factors remains controversial. Chromoendoscopy may be an important means to improve detection of colorectal neoplasia in IBD. Observational studies suggest that prolonged use of aminosalicylates is associated with decreased risk of neoplasia, but data are conflicting. A randomized trial of ursodeoxycholic acid in PSC showed decreased risk of colorectal neoplasia in patients receiving the drug relative to those on placebo. Copyright © 2004 by Current Science Inc.
引用
收藏
页码：506 / 513
页数：7
相关论文
共 96 条
  • [1] Orchard T.R., Chua C.N., Ahmad T., Et al., Uveitis and erythema nodosum in inflammatory bowel disease: Clinical features and the role of HLA genes, Gastroenterology, 123, pp. 714-718, (2002)
  • [2] Ricart E., Panaccione R., Loftus E.V., Et al., Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: A case-control study, Inflamm. Bowel Dis., 10, pp. 207-214, (2004)
  • [3] Manguso F., Sanges M., Staiano T., Et al., Cigarette smoking and appendectomy are risk factors for extraintestinal manifestations in ulcerative colitis, Am. J. Gastroenterol., 99, pp. 327-334, (2004)
  • [4] Salvarani C., Vlachonikolis I.G., van der Heijde D.M., Et al., Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients, Scand. J. Gastroenterol., 36, pp. 1307-1313, (2001)
  • [5] Bernstein C.N., Blanchard J.F., Rawsthorne P., Yu N., The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study, Am. J. Gastroenterol., 96, pp. 1116-1122, (2001)
  • [6] Palm O., Moum B., Ongre A., Gran J.T., Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: A population study (the IBSEN study), J. Rheumatol., 29, pp. 511-515, (2002)
  • [7] Steer S., Jones H., Hibbert J., Et al., Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease, J. Rheumatol., 30, pp. 518-522, (2003)
  • [8] Mielants H., Veys E., Cuvelier C., De Vos M., HLA B27 related arthritis and bowel inflammation. II. Ileocolonoscopy and bowel histology in patients with HLA B27 related arthritis, J. Rheumatol., 12, pp. 294-298, (1985)
  • [9] De Vos M., Mielants H., Cuvelier C., Et al., Long-term evolution of gut inflammation in patients with spondyloarthropathy, Gastroenterology, 110, pp. 1696-1703, (1996)
  • [10] Bjarnason I., Helgason K.O., Geirsson A.J., Et al., Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis, Gastroenterology, 125, pp. 1598-1605, (2003)
12345678910